GH changes
Pick any two versions below to diff them.
- Price
- $154.86 → $145.83(−5.8%)
- Recent events
- Nov added: 16, 2026: Guardant Health closed a private sale of $550 million of 0% convertible senior notes due 2032 on 16 November 2026. The sum includes a $50 million extra amount that buyers took in full. The initial conversion price is about $208.95 per share, a 35.0% premium to the 11 November 2026 share price. Nov 5, 2026: Guardant Health reported Q3 2026 results. Revenue rose 36% to $361.0 million, Oncology volume rose 58% to 117,000 tests and Shield volume rose to 83,000 tests. It raised 2026 revenue guidance to $1.36 billion to $1.37 billion and Shield volume to 285,000 to 290,000 tests. It now expects free cash flow burn of $205 million to $220 million, up from $195 million to $205 million. Nov 2, 2026: The board gave each of the two co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, 465,413 performance stock units at target. They vest only if the total shareholder return beats S&P 500 companies over three and five years, and at most 250% of target can vest. Nov 2, 2026: The board appointed Kevin R. Sayer, the Executive Chairman of Dexcom, as a director. Aug 1, 2026: UnitedHealth Group started to cover the Shield blood test for eligible members, the first major commercial insurer to cover adults age 45 or older at average risk of colorectal cancer. Apr 27, 2026: Guardant Health said that Craig Eagle, M.D., its Chief Medical Officer, would resign effective May 8, 2026.